RU2536270C1 - Комбинация для коррекции неврологического и психоэмоционального статуса при органических нарушениях цнс - Google Patents

Комбинация для коррекции неврологического и психоэмоционального статуса при органических нарушениях цнс Download PDF

Info

Publication number: RU2536270C1
Authority: RU; Russia
Prior art keywords: memantine; melatonin; amyloid; beta; mice
Prior art date: 2013-10-21

Application number

RU2013146812/15A

Other languages

English (en)

Russian (ru)

Inventor

Аллан Герович Бениашвили

Максим Эдуардович Запольский

Маргарита Алексеевна Морозова

Original Assignee

Общество с ограниченной ответственностью ООО "ВАЛЕНТА ИНТЕЛЛЕКТ"

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-10-21

Filing date

2013-10-21

Publication date

2014-12-20

2013-10-21 Application filed by Общество с ограниченной ответственностью ООО "ВАЛЕНТА ИНТЕЛЛЕКТ" filed Critical Общество с ограниченной ответственностью ООО "ВАЛЕНТА ИНТЕЛЛЕКТ"

2013-10-21 Priority to RU2013146812/15A priority Critical patent/RU2536270C1/ru

2014-05-21 Priority to PCT/RU2014/000362 priority patent/WO2015060746A1/fr

2014-12-20 Application granted granted Critical

2014-12-20 Publication of RU2536270C1 publication Critical patent/RU2536270C1/ru

Links

238000012937 correction Methods 0.000 title claims abstract description 6
BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims abstract description 138
229960004640 memantine Drugs 0.000 claims abstract description 137
YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims abstract description 70
DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims abstract description 70
229960003987 melatonin Drugs 0.000 claims abstract description 69
210000004556 brain Anatomy 0.000 claims abstract description 38
208000010877 cognitive disease Diseases 0.000 claims abstract description 8
230000035987 intoxication Effects 0.000 claims abstract description 8
231100000566 intoxication Toxicity 0.000 claims abstract description 8
230000007170 pathology Effects 0.000 claims abstract description 7
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
239000000203 mixture Substances 0.000 claims description 11
239000002552 dosage form Substances 0.000 claims description 5
239000002775 capsule Substances 0.000 claims description 4
239000007924 injection Substances 0.000 claims description 4
238000002347 injection Methods 0.000 claims description 4
239000000843 powder Substances 0.000 claims description 3
239000000829 suppository Substances 0.000 claims description 3
239000000443 aerosol Substances 0.000 claims description 2
230000006999 cognitive decline Effects 0.000 claims description 2
231100000216 vascular lesion Toxicity 0.000 claims description 2
239000000126 substance Substances 0.000 abstract description 54
230000000694 effects Effects 0.000 abstract description 41
238000002560 therapeutic procedure Methods 0.000 abstract description 3
241001465754 Metazoa Species 0.000 description 61
102000013455 Amyloid beta-Peptides Human genes 0.000 description 55
108010090849 Amyloid beta-Peptides Proteins 0.000 description 54
241000699670 Mus sp. Species 0.000 description 44
239000000243 solution Substances 0.000 description 34
238000012360 testing method Methods 0.000 description 26
238000002474 experimental method Methods 0.000 description 23
210000004027 cell Anatomy 0.000 description 18
210000003140 lateral ventricle Anatomy 0.000 description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
230000037396 body weight Effects 0.000 description 16
241000699666 Mus <mouse, genus> Species 0.000 description 15
210000001320 hippocampus Anatomy 0.000 description 14
229940068272 melatonin 3 mg Drugs 0.000 description 13
229920002472 Starch Polymers 0.000 description 11
230000009471 action Effects 0.000 description 11
229940113883 melatonin 6 mg Drugs 0.000 description 11
210000002569 neuron Anatomy 0.000 description 11
238000011160 research Methods 0.000 description 11
235000019698 starch Nutrition 0.000 description 11
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
230000004770 neurodegeneration Effects 0.000 description 10
238000007619 statistical method Methods 0.000 description 10
208000024827 Alzheimer disease Diseases 0.000 description 9
239000000839 emulsion Substances 0.000 description 9
LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 9
230000037023 motor activity Effects 0.000 description 8
230000000324 neuroprotective effect Effects 0.000 description 8
239000008107 starch Substances 0.000 description 8
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
230000003496 anti-amnesic effect Effects 0.000 description 7
230000030833 cell death Effects 0.000 description 7
239000003085 diluting agent Substances 0.000 description 7
206010027175 memory impairment Diseases 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
229920000881 Modified starch Polymers 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
230000034994 death Effects 0.000 description 6
239000007884 disintegrant Substances 0.000 description 6
208000035475 disorder Diseases 0.000 description 6
230000001073 episodic memory Effects 0.000 description 6
229960000967 memantine hydrochloride Drugs 0.000 description 6
238000012549 training Methods 0.000 description 6
238000007492 two-way ANOVA Methods 0.000 description 6
206010002091 Anaesthesia Diseases 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
230000037005 anaesthesia Effects 0.000 description 5
239000011230 binding agent Substances 0.000 description 5
210000003710 cerebral cortex Anatomy 0.000 description 5
239000003995 emulsifying agent Substances 0.000 description 5
229960001375 lactose Drugs 0.000 description 5
239000008101 lactose Substances 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
235000019426 modified starch Nutrition 0.000 description 5
239000008363 phosphate buffer Substances 0.000 description 5
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
229920000053 polysorbate 80 Polymers 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000008223 sterile water Substances 0.000 description 5
206010010904 Convulsion Diseases 0.000 description 4
238000000692 Student's t-test Methods 0.000 description 4
239000013543 active substance Substances 0.000 description 4
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 4
230000007423 decrease Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 4
230000001771 impaired effect Effects 0.000 description 4
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
230000003993 interaction Effects 0.000 description 4
230000008450 motivation Effects 0.000 description 4
238000001543 one-way ANOVA Methods 0.000 description 4
230000010412 perfusion Effects 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
-1 sublingual forms Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 3
208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 description 3
206010012289 Dementia Diseases 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
239000004201 L-cysteine Substances 0.000 description 3
235000013878 L-cysteine Nutrition 0.000 description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
238000000540 analysis of variance Methods 0.000 description 3
230000006907 apoptotic process Effects 0.000 description 3
230000003920 cognitive function Effects 0.000 description 3
230000006378 damage Effects 0.000 description 3
208000017004 dementia pugilistica Diseases 0.000 description 3
230000003492 excitotoxic effect Effects 0.000 description 3
231100000063 excitotoxicity Toxicity 0.000 description 3
229930195712 glutamate Natural products 0.000 description 3
230000006872 improvement Effects 0.000 description 3
230000003859 lipid peroxidation Effects 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
208000027061 mild cognitive impairment Diseases 0.000 description 3
230000016273 neuron death Effects 0.000 description 3
230000036542 oxidative stress Effects 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
XYGVIBXOJOOCFR-BTJKTKAUSA-N (z)-but-2-enedioic acid;8-chloro-6-(2-fluorophenyl)-1-methyl-4h-imidazo[1,5-a][1,4]benzodiazepine Chemical compound OC(=O)\C=C/C(O)=O.C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F XYGVIBXOJOOCFR-BTJKTKAUSA-N 0.000 description 2
UGBLISDIHDMHJX-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-one;hydrochloride Chemical compound [Cl-].COC1=CC=CC=C1N1CC[NH+](CCCC(=O)C=2C=CC(F)=CC=2)CC1 UGBLISDIHDMHJX-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 2
201000006474 Brain Ischemia Diseases 0.000 description 2
208000028698 Cognitive impairment Diseases 0.000 description 2
102000010906 Cyclooxygenase 1 Human genes 0.000 description 2
108010037464 Cyclooxygenase 1 Proteins 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
101000891092 Homo sapiens TAR DNA-binding protein 43 Proteins 0.000 description 2
208000023105 Huntington disease Diseases 0.000 description 2
102000001419 Melatonin receptor Human genes 0.000 description 2
108050009605 Melatonin receptor Proteins 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
208000036110 Neuroinflammatory disease Diseases 0.000 description 2
229930040373 Paraformaldehyde Natural products 0.000 description 2
208000018737 Parkinson disease Diseases 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
102100040347 TAR DNA-binding protein 43 Human genes 0.000 description 2
208000030886 Traumatic Brain injury Diseases 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000032683 aging Effects 0.000 description 2
230000003444 anaesthetic effect Effects 0.000 description 2
230000003078 antioxidant effect Effects 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000006399 behavior Effects 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
210000005013 brain tissue Anatomy 0.000 description 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
235000013539 calcium stearate Nutrition 0.000 description 2
239000008116 calcium stearate Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
230000027288 circadian rhythm Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
210000005110 dorsal hippocampus Anatomy 0.000 description 2
206010015037 epilepsy Diseases 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
229960003980 galantamine Drugs 0.000 description 2
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
244000144993 groups of animals Species 0.000 description 2
208000013403 hyperactivity Diseases 0.000 description 2
229960000905 indomethacin Drugs 0.000 description 2
238000001802 infusion Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000011835 investigation Methods 0.000 description 2
229960001021 lactose monohydrate Drugs 0.000 description 2
230000013016 learning Effects 0.000 description 2
230000006742 locomotor activity Effects 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
230000015654 memory Effects 0.000 description 2
239000004570 mortar (masonry) Substances 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
230000003959 neuroinflammation Effects 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
229920002866 paraformaldehyde Polymers 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000004224 protection Effects 0.000 description 2
230000033764 rhythmic process Effects 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
210000003625 skull Anatomy 0.000 description 2
229940023144 sodium glycolate Drugs 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000009529 traumatic brain injury Effects 0.000 description 2
JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 2
229930195727 α-lactose Natural products 0.000 description 2
229930195724 β-lactose Natural products 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
RFRMMZAKBNXNHE-UHFFFAOYSA-N 6-[4,6-dihydroxy-5-(2-hydroxyethoxy)-2-(hydroxymethyl)oxan-3-yl]oxy-2-(hydroxymethyl)-5-(2-hydroxypropoxy)oxane-3,4-diol Chemical compound CC(O)COC1C(O)C(O)C(CO)OC1OC1C(O)C(OCCO)C(O)OC1CO RFRMMZAKBNXNHE-UHFFFAOYSA-N 0.000 description 1
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
238000010175 APPswe/PSEN1dE9 Methods 0.000 description 1
102000012440 Acetylcholinesterase Human genes 0.000 description 1
108010022752 Acetylcholinesterase Proteins 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
208000031091 Amnestic disease Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
229940124638 COX inhibitor Drugs 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
208000032274 Encephalopathy Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000018899 Glutamate Receptors Human genes 0.000 description 1
108010027915 Glutamate Receptors Proteins 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
239000004368 Modified starch Substances 0.000 description 1
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
206010034719 Personality change Diseases 0.000 description 1
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
101710128242 TM2 domain-containing protein 1 Proteins 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
229940022698 acetylcholinesterase Drugs 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical class C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
238000004887 air purification Methods 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
230000006986 amnesia Effects 0.000 description 1
108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 1
108010061598 amyloid beta-protein (25-35) Proteins 0.000 description 1
FEWOUVRMGWFWIH-ILZZQXMPSA-N amyloid-beta polypeptide 40 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 FEWOUVRMGWFWIH-ILZZQXMPSA-N 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
239000003831 antifriction material Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000003050 axon Anatomy 0.000 description 1
238000009227 behaviour therapy Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
230000006931 brain damage Effects 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
230000001914 calming effect Effects 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000013339 cereals Nutrition 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
229960002327 chloral hydrate Drugs 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
229960005168 croscarmellose Drugs 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
229940096516 dextrates Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
229960002428 fentanyl Drugs 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
IRYFCWPNDIUQOW-UHFFFAOYSA-N fluanisone Chemical compound COC1=CC=CC=C1N1CCN(CCCC(=O)C=2C=CC(F)=CC=2)CC1 IRYFCWPNDIUQOW-UHFFFAOYSA-N 0.000 description 1
229960005220 fluanisone Drugs 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
238000002695 general anesthesia Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
229960001031 glucose Drugs 0.000 description 1
230000000285 glutaminergic effect Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000037417 hyperactivation Effects 0.000 description 1
230000000215 hyperchromic effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229960004903 invert sugar Drugs 0.000 description 1
VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
229950006874 kainic acid Drugs 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
238000000034 method Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000004899 motility Effects 0.000 description 1
229920001206 natural gum Polymers 0.000 description 1
230000007171 neuropathology Effects 0.000 description 1
230000004112 neuroprotection Effects 0.000 description 1
239000004090 neuroprotective agent Substances 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
238000011302 passive avoidance test Methods 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
208000022821 personality disease Diseases 0.000 description 1
239000005426 pharmaceutical component Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000037081 physical activity Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000001012 protector Effects 0.000 description 1
230000002488 pyknotic effect Effects 0.000 description 1
GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000021907 regulation of circadian rhythm Effects 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
210000005245 right atrium Anatomy 0.000 description 1
239000000523 sample Substances 0.000 description 1
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
229960002646 scopolamine Drugs 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
229940071117 starch glycolate Drugs 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000006068 taste-masking agent Substances 0.000 description 1
102000013498 tau Proteins Human genes 0.000 description 1
108010026424 tau Proteins Proteins 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
238000007473 univariate analysis Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000031836 visual learning Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

RU2013146812/15A 2013-10-21 2013-10-21 Комбинация для коррекции неврологического и психоэмоционального статуса при органических нарушениях цнс RU2536270C1 (ru)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
RU2013146812/15A RU2536270C1 (ru)	2013-10-21	2013-10-21	Комбинация для коррекции неврологического и психоэмоционального статуса при органических нарушениях цнс
PCT/RU2014/000362 WO2015060746A1 (fr)	2013-10-21	2014-05-21	Combinaison pour traiter et/ou prévenir l'apparition de troubles psychiques, cognitifs, comportementaux et neurologiques lors de maladies organiques du système nerveux central de genèse diverse

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
RU2013146812/15A RU2536270C1 (ru)	2013-10-21	2013-10-21	Комбинация для коррекции неврологического и психоэмоционального статуса при органических нарушениях цнс

Publications (1)

Publication Number	Publication Date
RU2536270C1 true RU2536270C1 (ru)	2014-12-20

Family

ID=52993225

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2013146812/15A RU2536270C1 (ru)	2013-10-21	2013-10-21	Комбинация для коррекции неврологического и психоэмоционального статуса при органических нарушениях цнс

Country Status (2)

Country	Link
RU (1)	RU2536270C1 (fr)
WO (1)	WO2015060746A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2623865C1 (ru) *	2016-06-29	2017-06-29	Общество С Ограниченной Ответственностью "Валента-Интеллект"	Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2654713C1 (ru) *	2016-06-29	2018-05-22	Общество С Ограниченной Ответственностью "Валента-Интеллект"	Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина
WO2018004391A1 (fr) *	2016-06-29	2018-01-04	Общество С Ограниченной Ответственностью "Валента-Интеллект"	Composition pharmaceutique contenant une combinaison de mémantine et de mélatonine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050031651A1 (en) *	2002-12-24	2005-02-10	Francine Gervais	Therapeutic formulations for the treatment of beta-amyloid related diseases
US20130116215A1 (en) *	2011-10-28	2013-05-09	Mireia Coma	Combination therapies for treating neurological disorders
RU2488388C1 (ru) *	2012-05-24	2013-07-27	Ооо "Валента Интеллект"	Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств

2013
- 2013-10-21 RU RU2013146812/15A patent/RU2536270C1/ru active
2014
- 2014-05-21 WO PCT/RU2014/000362 patent/WO2015060746A1/fr not_active Ceased

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050031651A1 (en) *	2002-12-24	2005-02-10	Francine Gervais	Therapeutic formulations for the treatment of beta-amyloid related diseases
US20130116215A1 (en) *	2011-10-28	2013-05-09	Mireia Coma	Combination therapies for treating neurological disorders
RU2488388C1 (ru) *	2012-05-24	2013-07-27	Ооо "Валента Интеллект"	Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Энциклопедический словарь медицинских терминов, под редакцией академика РАМН В.И. Покровского, издание 2-е, Москва "Медицина", 2001, стр.648,30 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2623865C1 (ru) *	2016-06-29	2017-06-29	Общество С Ограниченной Ответственностью "Валента-Интеллект"	Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина

Also Published As

Publication number	Publication date
WO2015060746A1 (fr)	2015-04-30

Publication	Publication Date	Title
JP6560325B2 (ja)	2019-08-14	軸索再生および神経機能を促進するための方法および組成物
KR101581611B1 (ko)	2015-12-31	정신, 행동, 인지 장애의 예방 및 치료용 약학적 조성물
TW200418460A (en)	2004-10-01	Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
JP2022536017A (ja)	2022-08-12	精神障害、行動障害、認知障害を処置する方法
TW201636024A (zh)	2016-10-16	阿吡莫德組成物及其使用方法
JP2012500801A (ja)	2012-01-12	Ｃｎｓ疾患の治療法
Wang et al.	2016	Intranasal administration of Exendin-4 antagonizes Aβ31–35-induced disruption of circadian rhythm and impairment of learning and memory
RU2536270C1 (ru)	2014-12-20	Комбинация для коррекции неврологического и психоэмоционального статуса при органических нарушениях цнс
JP2022065024A (ja)	2022-04-26	ヘテロシクリデンアセトアミド誘導体含有医薬
CN111432814B (zh)	2024-05-14	用于减轻或治疗包括脆性X染色体综合征、Angelman综合征或Rett综合征的发育障碍的氨基甲酸酯化合物的用途
CN102099033B (zh)	2012-10-24	用于治疗纤维肌痛症的药物组合物
JP2021505647A (ja)	2021-02-18	化学療法誘発性の医原性疼痛の治療に使用するためのＣ５ａＲ阻害薬
JP7744419B2 (ja)	2025-09-25	レット症候群を治療するためのプリドピジンまたはその類似体の使用
Kumar et al.	2025	Enhanced neuroprotection in experiment multiple sclerosis through combined rosiglitazone and probiotic-loaded solid lipid nanoparticles: modulation of cellular signaling pathways
US12447135B2 (en)	2025-10-21	Fenchol as a stimulator of free fatty acid receptor and other uses thereof
KR102428383B1 (ko)	2022-08-02	중추신경계 및 혈관계에 대한 활성을 가진 벤조디아제핀 생성물
JP7249433B2 (ja)	2023-03-30	蜂毒抽出物を有効成分として含有する神経炎症疾患の予防または治療用組成物
CN107875144A (zh)	2018-04-06	一种治疗抑郁症的口服药物组合物
RU2561588C2 (ru)	2015-08-27	Способ лечения гиперкортизолемии, головных болей, нейропатической боли и родственных расстройств
CN105748460B (zh)	2018-11-02	一种治疗老年痴呆的药物
CN112789044A (zh)	2021-05-11	使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物
CN105497021A (zh)	2016-04-20	胺类化合物治疗焦虑障碍的医药用途
KR20190054559A (ko)	2019-05-22	염증성 통증 또는 염증성 질환에서 기인한 통증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
WO2025088452A1 (fr)	2025-05-01	Substance artificielle et son procédé de préparation
WO2025162430A1 (fr)	2025-08-07	Combinaison de médicaments et son utilisation dans la prévention ou le traitement d'une maladie neurodégénérative

RU2536270C1 - Комбинация для коррекции неврологического и психоэмоционального статуса при органических нарушениях цнс - Google Patents

Info

Links

Images

Classifications

Landscapes

Priority Applications (2)

Applications Claiming Priority (1)

Publications (1)

Family

ID=52993225

Family Applications (1)

Country Status (2)

Cited By (1)

Families Citing this family (2)

Citations (3)

Patent Citations (3)

Non-Patent Citations (1)

Cited By (1)

Also Published As

Similar Documents